Previous 10 | Next 10 |
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan® (Regadenoson) injec...
2023-04-21 07:53:42 ET Dr. Reddy's Laboratories ( NYSE: RDY ) said it launched Treprostinil Injection in the U.S. market. The drug is a generic version of United Therapeutics' ( NASDAQ: UTHR ) Remodulin (treprostinil) injection, which is approved in the U.S. ...
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), today announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin® (treprost...
2023-04-20 09:09:50 ET Aditxt ( NASDAQ: ADTX ) signed an agreement with Cellvera to get 50% ownership in G Response Aid FZE (GRA or Global Response Aid) for $24.5M and royalties. Aditxt noted that it will partner with logistics company Agility, owing the remaining 50%...
Dr. Reddy's Laboratories Limited (NYSE: RDY) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 2.57% on the day to $60.25. Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated p...
Shares of Dr. Reddy's Laboratories Limited (NYSE: RDY) traded at a new 52-week high today and are currently trading at $58.71. So far today, approximately 48,384 shares have been exchanged, as compared to an average 30-day volume of 245.96k shares. Dr. Reddy's Laboratories Limited, together w...
2023-03-30 09:29:12 ET After a 7% rise in the previous session, Citius Pharma ( NASDAQ: CTXR ) shares continued to gain in the pre-market Thursday after the company highlighted its progress on its previously announced plans to spin off oncology candidate I/ONTAK into a standal...
2023-03-24 07:29:58 ET GSK ( NYSE: GSK ) said it disagrees with a California state court ruling in respect to the Goetz case related to the company's heartburn drug Zantac (ranitidine). The British pharma giant said that after 13 epidemiological studies conducted lookin...
COYA 302 is an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig (Abatacept). COYA 302 has a dual mechanism of action intended to suppress the chronic and sustained inflammation underlying certain neurodegenerative diseases. COYA 301 ...
Summary Aikya Investment Management is an independent, employee-owned, investment management company that specialises in managing Emerging Markets equity portfolios. We believe that by investing with good stewards of capital, we can navigate the volatility of Emerging Markets whil...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...